Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Raghunath

Up 283% YTD, Is It Too Late to Buy Viking Therapeutics Stock?

While Nvidia (NVDA) and its Big Tech peers have driven the S&P 500 Index ($SPX) to new all-time highs this year, several other growth stocks across multiple sectors are flying under the radar. One of these names is biotech stock Viking Therapeutics (VKTX), which has returned 283% so far in 2024, and is up 520% in the last 12 months. 

Valued at a market cap of $7.43 billion, the mid-cap pharmaceutical company also trades 28% below its February all-time highs, after losing close to 19% in a single trading session this Thursday. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.